Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20230903059343N1
IRCT20230903059343N1
Not yet recruiting
Phase 2

Comparing the effect of Empagliflozin, Pioglitazone and their combination, on sonographic and biochemical features of non-alcoholic fatty liver disease in diabetic patients

Arak University of Medical Sciences0 sites120 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
on-alcoholic fatty liver disease.
Sponsor
Arak University of Medical Sciences
Enrollment
120
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •All patients with type 2 diabetes phenotype and fatty liver disease

Exclusion Criteria

  • •History of alcohol ingestion
  • •Heart failure, NYHA class III or IV
  • •Chronic kidney disease with GFR\<45 ml/min
  • •Other chronic liver diseases including viral or autoimmune hepatitis
  • •Current use of Empagliflozine or Pioglitazone
  • •Use of known causative drugs for fatty liver including NSAIDs, Tamoxifen, Amiodarone and Valproate
  • •Use of antioxidant agents during the past 3 months, including Vitamin C, Zinc or Selenium\-containing supplements.
  • •HbA1c less than 7 or more than 9 percent
  • •Type 1 diabetes or diabetes due to a specific secondary cause
  • •Pregnancy or Lactation

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Comparing the effect of Empagliflozin with Pioglitazone on nonalcoholic fatty liver
IRCT20220928056051N1Oroumia University of Medical Sciences60
Completed
Phase 2
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patients
IRCT20190122042450N3Iran University of Medical Sciences105
Not yet recruiting
Phase 2
The effect of Empagliflozin on nonalcoholic fatty liver disease in non-diabetic patientson alcoholic fatty liver disease.Nonalcoholic steatohepatitis [NASH]K75.81
IRCT20190122042450N1Iran University of Medical Sciences100
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02
IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Recruiting
Phase 2
The cardiac effect of pioglitazone and empagliflozin among diabetic patients with NAFLDCondition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.Nonalcoholic steatohepatitis (NASH)Type 2 diabetesCardiomyopathyK75.81
IRCT20190122042450N5Iran University of Medical Sciences70